Are the presently accredited antibody therapies used to deal with people at elevated danger for extreme COVID-19 illness additionally efficient in opposition to presently circulating viral variants? A latest research exhibits that the Omicron sub-lineage BQ.1.1, presently on the rise worldwide, is immune to all accredited antibody therapies.